Patent · US Expired

Amino substituted pyrimidines and triazines

US6288060A · kind A · utility

3Cited by
1References
13Claims
0Family size

Assignees

Inventors

Key dates

Filing dateApr 15, 1998
Grant dateSep 11, 2001
Priority date
Expiry dateApr 15, 2018

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D251/14
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

Pyrimidines and triazines of formula (I) ##STR1## wherein R is C.sub.1-6 alkyl, amino, mono- or diC.sub.1-6 alkylamino; R.sup.1 is hydrogen, C.sub.1-6 alkyl, C.sub.3-6 alkenyl, hydroxyC.sub.1-6 alkyl or C.sub.1-6 alkyloxy-C.sub.1-6 alkyl; R.sup.2 is C.sub.1-6 alkyl, mono- or diC.sub.3-6 cycloalkylmethyl, phenylmethyl, substituted phenylmethyl, C.sub.1-6 alkyloxy-C.sub.1-6 alkyl, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkyloxycarbonylC.sub.1-6 alkyl, C.sub.3-6 alkenyl; or R.sup.1 and R.sup.2 taken together with the nitrogen to which they are attached may form a pyrrolidinyl, morpholinyl or piperidinyl group; X is N or CR.sup.3 ; R.sup.3 is hydrogen or C.sub.1-6 alkyl; R.sup.4 is phenyl or substituted phenyl; A is ##STR2## PA1 or --CR.sup.7 R.sup.8 -- wherein R.sup.5 and R.sup.6 each independently are hydrogen or C.sub.1-4 alkyl; R.sup.7 is hydrogen or OH, R.sup.8 is hydrogen or C.sub.1-6 alkyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing these compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.